Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. Borsa (REGN) Ultime notizie

Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag

Zacks Investment Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Zacks Investment Research

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

GlobeNewswire Inc.

Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates

Zacks Investment Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Zacks Investment Research

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

GlobeNewswire Inc.

Wall Street Breakfast: The Week Ahead

Seeking Alpha

Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y

Zacks Investment Research

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Zacks Investment Research

Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts

Benzinga

Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?

Benzinga

Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales

Zacks Investment Research

Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Investment Research

3 Biotech Stocks to Buy and Hold Through 2030 and Beyond

The Motley Fool

Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire Inc.

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Zacks Investment Research

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

Zacks Investment Research

Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround

Zacks Investment Research

Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

Zacks Investment Research

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

GlobeNewswire Inc.

EXEL vs. REGN: Which Stock Is the Better Value Option?

Zacks Investment Research

Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?

Zacks Investment Research

Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up

Zacks Investment Research

Regeneron (REGN) Reports Next Week: What You Should Expect

Zacks Investment Research

The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power

Zacks Investment Research

Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks

Zacks Investment Research

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

GlobeNewswire Inc.

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

Zacks Investment Research

2 Small-Cap Growth Stocks With Room to Run

The Motley Fool

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

GlobeNewswire Inc.

Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?

Zacks Investment Research

Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success

Zacks Investment Research

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick

Benzinga

2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why

Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks Investment Research

Why Regeneron (REGN) Could Beat Earnings Estimates Again

Zacks Investment Research

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

Zacks Investment Research

Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views

Benzinga

EXEL or REGN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

GlobeNewswire Inc.

Should You Sell This Stock Following a Regulatory Roadblock?

The Motley Fool

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Zacks Investment Research

Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks

Zacks Investment Research

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

GlobeNewswire Inc.

Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates

Zacks Investment Research

Stock-Split Watch: Are These 2 Top Growth Stocks Next?

The Motley Fool

Should You Invest in the iShares Biotechnology ETF (IBB)?

Zacks Investment Research

Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA

Zacks Investment Research

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals

Benzinga

Regeneron Provides Update on Biologics License Application for Odronextamab

GlobeNewswire Inc.